BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Campos MA, Alazemi S, Zhang G, Salathe M, Wanner A, Sandhaus RA, Baier H. Clinical characteristics of subjects with symptoms of alpha1-antitrypsin deficiency older than 60 years. Chest 2009;135:600-8. [PMID: 19017884 DOI: 10.1378/chest.08-1129] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 1.6] [Reference Citation Analysis]
Number Citing Articles
1 Scichilone N. Comorbidities of Lung Disease in the Elderly. Clin Geriatr Med 2017;33:597-603. [PMID: 28991653 DOI: 10.1016/j.cger.2017.06.010] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
2 Stockley RA. Alpha1-antitrypsin Review. Clinics in Chest Medicine 2014;35:39-50. [DOI: 10.1016/j.ccm.2013.10.001] [Cited by in Crossref: 47] [Cited by in F6Publishing: 44] [Article Influence: 6.7] [Reference Citation Analysis]
3 Bradi AC, Audisho N, Casey DK, Chapman KR. Alpha-1 antitrypsin deficiency in Canada: regional disparities in diagnosis and management. COPD 2015;12 Suppl 1:15-21. [PMID: 25938286 DOI: 10.3109/15412555.2015.1021908] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
4 Edgar RG, Patel M, Bayliss S, Crossley D, Sapey E, Turner AM. Treatment of lung disease in alpha-1 antitrypsin deficiency: a systematic review. Int J Chron Obstruct Pulmon Dis 2017;12:1295-308. [PMID: 28496314 DOI: 10.2147/COPD.S130440] [Cited by in Crossref: 33] [Cited by in F6Publishing: 13] [Article Influence: 8.3] [Reference Citation Analysis]
5 Kalsheker NA. α 1 -Antitrypsin deficiency: best clinical practice. J Clin Pathol 2009;62:865-9. [DOI: 10.1136/jcp.2008.063495] [Cited by in Crossref: 26] [Cited by in F6Publishing: 18] [Article Influence: 2.2] [Reference Citation Analysis]
6 McGrady T, Mannino DM, Malanga E, Thomashow BM, Walsh J, Sandhaus RA, Stoller JK. Characteristics of Chronic Obstructive Pulmonary Disease (COPD) Patients Reporting Alpha-1 Antitrypsin Deficiency in the WebMD Lung Health Check Database. Chronic Obstr Pulm Dis 2015;2:141-51. [PMID: 28848838 DOI: 10.15326/jcopdf.2.2.2015.0160] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
7 Stockley RA. Alpha-1 Antitrypsin Deficiency: Phenotypes and Quality of Life. Ann Am Thorac Soc 2016;13 Suppl 4:S332-5. [PMID: 27564669 DOI: 10.1513/AnnalsATS.201507-436KV] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
8 Holm KE, Plaufcan MR, Ford DW, Sandhaus RA, Strand M, Strange C, Wamboldt FS. The impact of age on outcomes in chronic obstructive pulmonary disease differs by relationship status. J Behav Med 2014;37:654-63. [PMID: 23645147 DOI: 10.1007/s10865-013-9516-7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
9 Henao MP, Craig TJ. Recent advances in understanding and treating COPD related to α1-antitrypsin deficiency. Expert Rev Respir Med 2016;10:1281-94. [PMID: 27771979 DOI: 10.1080/17476348.2016.1249851] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
10 Eden E, Turino GM. α 1 -Antitrypsin Deficiency. Chest 2009;135:591-2. [DOI: 10.1378/chest.08-2622] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
11 Campos MA, Lascano J. α1 Antitrypsin deficiency: current best practice in testing and augmentation therapy. Ther Adv Respir Dis 2014;8:150-61. [PMID: 25013223 DOI: 10.1177/1753465814542243] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.9] [Reference Citation Analysis]
12 Holm KE, Borson S, Sandhaus RA, Ford DW, Strange C, Bowler RP, Make BJ, Wamboldt FS. Differences in adjustment between individuals with alpha-1 antitrypsin deficiency (AATD)-associated COPD and non-AATD COPD. COPD 2013;10:226-34. [PMID: 23547634 DOI: 10.3109/15412555.2012.719049] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
13 Pierucci P, Lenato GM, Suppressa P, Lastella P, Triggiani V, Valerio R, Comelli M, Salvante D, Stella A, Resta N, Logroscino G, Resta F, Sabbà C. A long diagnostic delay in patients with Hereditary Haemorrhagic Telangiectasia: a questionnaire-based retrospective study. Orphanet J Rare Dis 2012;7:33. [PMID: 22676497 DOI: 10.1186/1750-1172-7-33] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 4.2] [Reference Citation Analysis]
14 Manca S, Rodriguez E, Huerta A, Torres M, Lazaro L, Curi S, Pirina P, Miravitlles M. Usefulness of the CAT, LCOPD, EQ-5D and COPDSS Scales in Understanding the Impact of Lung Disease in Patients with Alpha-1 Antitrypsin Deficiency. COPD: Journal of Chronic Obstructive Pulmonary Disease 2014;11:480-8. [DOI: 10.3109/15412555.2014.898030] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
15 McGrady T, Mannino DM, Malanga E, Thomashow BM, Walsh J, Sandhaus RA, Stoller JK. Characteristics of Chronic Obstructive Pulmonary Disease (COPD) Patients Reporting Alpha-1 Antitrypsin Deficiency in the WebMD Lung Health Check Database. Chronic Obstr Pulm Dis 2015;2:141-51. [PMID: 28848838 DOI: 10.15326/jcopdf.2.2.2015.0160] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
16 Stockley RA, Halpin DMG, Celli BR, Singh D. Chronic Obstructive Pulmonary Disease Biomarkers and Their Interpretation. Am J Respir Crit Care Med 2019;199:1195-204. [DOI: 10.1164/rccm.201810-1860so] [Cited by in Crossref: 36] [Cited by in F6Publishing: 18] [Article Influence: 18.0] [Reference Citation Analysis]
17 Miskoff JA, Khan B, Chaudhri M, Phan H, Carson MP. Identifying Alpha-1 Antitrypsin Deficiency Based on Computed Tomography Evidence of Emphysema. Cureus 2019;11:e3971. [PMID: 30956923 DOI: 10.7759/cureus.3971] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
18 Miravitlles M, Dirksen A, Ferrarotti I, Koblizek V, Lange P, Mahadeva R, Mcelvaney NG, Parr D, Piitulainen E, Roche N, Stolk J, Thabut G, Turner A, Vogelmeier C, Stockley RA. European Respiratory Society statement: diagnosis and treatment of pulmonary disease in α 1 -antitrypsin deficiency. Eur Respir J 2017;50:1700610. [DOI: 10.1183/13993003.00610-2017] [Cited by in Crossref: 123] [Cited by in F6Publishing: 91] [Article Influence: 30.8] [Reference Citation Analysis]
19 Stockley RA, Miravitlles M, Vogelmeier C; Alpha One International Registry (A.I.R.). Augmentation therapy for alpha-1 antitrypsin deficiency: towards a personalised approach. Orphanet J Rare Dis 2013;8:149. [PMID: 24063809 DOI: 10.1186/1750-1172-8-149] [Cited by in Crossref: 52] [Cited by in F6Publishing: 45] [Article Influence: 6.5] [Reference Citation Analysis]
20 Greene CM, Marciniak SJ, Teckman J, Ferrarotti I, Brantly ML, Lomas DA, Stoller JK, McElvaney NG. α1-Antitrypsin deficiency. Nat Rev Dis Primers 2016;2:16051. [PMID: 27465791 DOI: 10.1038/nrdp.2016.51] [Cited by in Crossref: 103] [Cited by in F6Publishing: 98] [Article Influence: 20.6] [Reference Citation Analysis]
21 Petrache I, Hajjar J, Campos M. Safety and efficacy of alpha-1-antitrypsin augmentation therapy in the treatment of patients with alpha-1-antitrypsin deficiency. Biologics 2009;3:193-204. [PMID: 19707408 DOI: 10.2147/btt.2009.3088] [Cited by in Crossref: 2] [Cited by in F6Publishing: 30] [Article Influence: 0.2] [Reference Citation Analysis]
22 Eden E. Asthma and COPD in alpha-1 antitrypsin deficiency. Evidence for the Dutch hypothesis. COPD 2010;7:366-74. [PMID: 20854052 DOI: 10.3109/15412555.2010.510159] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]